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Abstract
Purpose
Danshen is the dried root extract of the plant Salvia Miltiorrhiza and it is used as traditional
Chinese medicinal herbal product to prevent and treat atherosclerosis. However, its efficacy
has not been thoroughly investigated. This study evaluates the effect of Danshen on hyperlip-
idemia and hypertension, two well known risk factors for the development of atherosclerosis.
Methods
This was a randomized, placebo-controlled, double-blind crossover study performed at a
tertiary referral center. Participants were recruited by newspaper advertisement and ran-
domized to treatment with Danshen (water-extract of the Salvia Miltiorrhiza root) or placebo
for 4 consecutive weeks. There was a wash out period of 4 weeks. Of the 20 analysed par-
ticipants, 11 received placebo first. Inclusion criteria were: age 40-70 years, hyperlipidemia
and hypertension. At the end of each treatment period, plasma lipids were determined (pri-
mary outcome), 24 hours ambulant blood pressure measurement (ABPM) was performed,
and vasodilator endothelial function was assessed in the forearm.
Results
LDL cholesterol levels were 3.82±0.14 mmol/l after Danshen and 3.52±0.16 mmol/l after
placebo treatment (mean±SE; p<0.05 for treatment effect corrected for baseline). Danshen
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treatment had no effect on blood pressure (ABPM 138/84 after Danshen and 136/87 after
placebo treatment). These results were further substantiated by the observation that Dan-
shen had neither an effect on endothelial function nor on markers of inflammation, oxidative
stress, glucose metabolism, hemostasis and blood viscosity.
Conclusion
Four weeks of treatment with Danshen (water-extract) slightly increased LDL-cholesterol
without affecting a wide variety of other risk markers. These observations do not support the
use of Danshen to prevent or treat atherosclerosis.
Trial Registration
ClinicalTrials.gov NCT01563770
Introduction
Worldwide, cardiovascular disease (atherosclerosis) is the leading cause of mortality[1]. Tradi-
tional risk factors for atherosclerosis are hyperlipidemia, hypertension, diabetes mellitus,
smoking and inflammation, which has gained much attention more recently[2, 3]. In both pri-
mary and secondary prevention, treatment of hypertension and hyperlipidemia reduces the
risk of cardiovascular events[4–6].
Traditional Chinese Medicine (TCM) has been playing an important role in healthcare in
Asia for hundreds of years. Recently, there is an upsurge in the popularity of TCM products
among consumers outside China. In 2010, the United States spent $7.6 billion on TCM prod-
ucts and Europe $2 billion [7]. Factors that contribute to the increased use of TCM products
are the increased prevalence of obesity and related chronic disorders, increasing costs of con-
ventional medicines and the belief that TCM products are safer and more effective than pre-
scription drugs [8].
Danshen is the dried root extract of the plant Salvia Miltiorrhiza and is widely used in Asia
to treat coronary artery disease, hyperlipidemia and cerebrovascular disease[9]. The estimated
number of patients using Danshen is approximately 5 million worldwide[10]. According to
TCM theory, Danshen is used in patients to treat “blood stasis” as it “moves blood” [11]. The
TCM-qualification of “blood stasis” is made by identification of certain changes in the tongue
and pulse. The major components of Danshen are hydrophilic salvianolic acids and lipophilic
tanshinones[12]. In vitro treatment of human monocyte derived macrophages with a combina-
tion of Danshen and Gegen resulted in a suppression of acetylated Low Density Lipoprotein
(LDL) uptake [13]. Two active components of Danshen, salvianolic acid A and magnesium
tanshinoate B, inhibit LDL oxidation [11]. A mixture of Chinese herbs, including Danshen, has
been shown to exert beneficial effects on high-fat diet induced metabolic syndrome in rats [14].
Also in humans, Danshen may reduce LDL-levels and blood pressure [11]. However, the qual-
ity of randomized clinical trials of Danshen is poor [15–17] and not easily accessible to West-
ern physicians since most are published in Chinese.
Therefore, this study was designed to evaluate the effect of Danshen on hyperlipidemia and
hypertension, two well validated risk factors for cardiovascular disease according to evidence-
based medicine.
Danshen and Cardiovascular Risk Factors
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Patients and Methods
Study Population
The study population consisted of 20 subjects aged 40–70 years with hyperlipidemia and
hypertension, who were recruited through advertisements in local newspapers (Fig 1). Included
were subjects with a fasting LDL cholesterol> 3.5 mmol/l and/or triglycerides > 1.7 mmol/l.
Patients treated with antihypertensive drugs were eligible when the average of three office
blood pressure recordings (sphygmomanometer, sitting position, at least 5 minutes interval)
revealed a systolic blood pressure> 140 mmHg and/or diastolic blood pressure> 90 mmHg.
For subjects that were not treated with antihypertensives, blood pressure was recorded three
times on two separate visits (in total 6 recordings, in sitting position, sphygmomanometer, 5
minute intervals between recordings on each visit) and again average blood pressure had to ful-
fill the criterium of> 140 mmHg for systolic and/or> 90 mmHg for diastolic blood pressure.
Excluded were subjects with triglycerides> 8 mmol/l and/or LDL-cholesterol> 5 mmol/l or
systolic blood pressure> 180 mmHg and/or diastolic blood pressure> 110 mmHg. Further
exclusion criteria were treatment with statins, use of more than 1 antihypertensive drug, use of
angiotensin-converting-enzyme inhibitors, angiotensin II receptor antagonists, calcium antag-
onists or vitamin and/or herbal supplements, diabetes mellitus treated with insulin, a history of
cardiovascular disease, use of anticoagulant drugs, a serum alanine aminotransferase or aspar-
tate aminotransferase level of more than 3 times the upper limit of normal and abnormal crea-
tinin clearance defined as MDRD< 60 ml/min/1.73m2. The exclusion of angiotensin
converting enzyme inhibitors, angiotensin II receptor antagonists and calcium antagonists was
based on documented improvement by these drugs of acetylcholine-induced forearm vasodila-
tion, as opposed to non-dilating beta blockers and thiazide diuretics [18–21]. Therefore, failure
to exclude these drugs could bias acetylcholine-induced vasodilation which was one of the sec-
ondary endpoints.
Fig 1. CONSORT flow diagram. SAE: Serious Adverse Event. The SAE (Bell’s palsy) occurred during
Danshen treatment (see text).
doi:10.1371/journal.pone.0128695.g001
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Protocol
This was a randomized, double-blind, placebo controlled crossover study performed at a ter-
tiary referral center (Fig 2). After inclusion in the study, subjects were randomly assigned to
treatment with Danshen capsules, 4 capsules of 500 mg tid, for 28 days or placebo capsules, 4
capsules tid, for 28 days. After a washout period of 4 weeks participants crossed over to the
other treatment arm. Investigational medication was given on top of their other medication.
Participants were contacted by telephone halfway each treatment period to check for com-
pliance and possible side effects.
At the end of each treatment period blood was collected, blood pressure, body weight and
endothelium-mediated vasodilation were measured, and potential side effects were recorded.
Compliance was monitored by pill counts. Prescribed medication was not altered during the
trial and participants did not change their dietary habits. Plasma lipids were the primary out-
come and blood pressure was the secondary outcome of this trial. All other outcome parame-
ters are exploratory.
Salvia miltiorrhiza root water-extract (Danshen), randomization
procedure and blinding
Salvia miltiorrhiza extract was produced by Kaiser Pharmaceuticals Co. in Taiwan. This prod-
uct was obtained from a specialized pharmacy NatuurApotheek. Using this extract, Basic
Pharma Manufacturing BV produced Danshen and placebo capsules. Each capsule contained
500 mg granulate consisting of 50% water-extract of Danshen and 50% starch. Therefore, a
dosage of 4 capsules tid with 500 mg granulate is equal to 4 capsules with 250 mg extract tid (3
g daily). Since the root—extract ratio is 5:1, 3 gram extract originates from 15 g root. The Phar-
macopoeia of the People’s Republic of China recommends a dosage of 9–15 g root daily [10].
So, we used in this study the highest dose of Danshen that is regularly used in TCM. In this
way, we wanted to reduce any doubts about insufficient dosing in case of lack of efficacy or
overdosing in case of unexpected adverse events.
Fig 2. Graphic presentation of the study protocol. Four weeks treatment with Danshen and placebo in a
crossover design with at least four weeks of washout (represented in the figure as the period between week 4
and week 8). BP = blood pressure. ABPM = 24-h Ambulatory Blood Pressure Monitoring. TCM = traditional
Chinese Medicine diagnosis.
doi:10.1371/journal.pone.0128695.g002
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Briefly, the production process of Danshen is as follows: first a water decoction of Salvia
root is made. Subsequently, the water-extract is concentrated 5 times via a standard distillation
procedure. After the concentration procedure, a drying and granulation procedure (with 50%
starch as carrier) followed using a fluid bed spray dryer. Then the granules are filtered, which
results in a final bulk product consisting of granules of a specified size. Finally, the bulk product
is filled into containers. The NatuurApotheek also prepared the placebo’s according to Good
Manufacuring Practice and filled these in equally appearing containers. Placebo and Danshen
capsules were similar in appearance. The labels of the containers included the randomization
number (two containers (placebo and Danshen) per randomization number), and period num-
ber. The Natuurapotheek performed the randomization. The randomization list which linked
randomization number to treatment order, was stored at a safe place at the Clinical Research
Centre Nijmegen. Participants received a number according to inclusion order and received
the medication with randomization number that equaled the inclusion number. The research
team involved in recruitment, assessment of primary, secondary and explorative outcome mea-
surements (including laboratory personnel) and data entry as well as participants remained
blinded until all data had been entered in the database and the database had been monitored by
an independent trial monitor.
Biochemical analyses
Lipids. Blood was drawn in fasting state before and after each treatment period to measure
total cholesterol, triglycerides, HDL-cholesterol and apolipoprotein B. The LDL- cholesterol
was calculated using the Friedewald equation (LDL-cholesterol = total cholesterol—HDL-cho-
lesterol– 0.45 x triglycerides) [22]. Total cholesterol and triglyceride concentrations were mea-
sured using an enzymatic method. For determination of HDL-levels, direct immunoinhibition
was used. Apolipoprotein B levels were determined by turbidimetry (all Architect, Abbott
Diagnostics Division). Coefficients of variation were for total cholesterol<3%, triglycerides
<5%, HDL-cholesterol4% and for apolipoprotein B6.5%.
Metabolic and inflammatory parameters. Glucose concentrations were measured using
the glucose oxidase-peroxidase method. (Architect, Abbott Diagnostics Division). Insulin levels
were determined by an electrochemiluminescence immunoassay (Modular E170, Roche Diag-
nostics). The coefficients of variation were 5% for glucose and 3.2% for insulin.
Homeostasis model assessment of insulin sensitivity (HOMA IR) was calculated using the
following formula: fasting glucose (mmol/l) x fasting insulin (mU/l)/ 22.5. For Homeostasis
Model Assessment (HOMA) of beta cell function (HOMA-B) the formula was: 20x fasting
insulin (mU/l)/ fasting glucose (mmol/l)-3.5 [23].
As marker of oxidative stress, lipid peroxidation was determined by measuring ThioBarbi-
turic Acid Reactive Substances (TBARS) in plasma using a fluorimetric assay [24]. Further-
more, antioxidant capacity was determined by means of Ferric Reducing Ability of Plasma
assay (FRAP) [25].
Measurements of safety parameters (hemogram, electrolytes, creatinin and liver enzymes)
were performed at the department of Laboratory Medicine, Radboud university medical center.
Blood pressure measurement
Before start of study medication, blood pressure was measured for 20 minutes at two minute
intervals by an automated device (Nihon Kohden BSM 2301, Nihon Kohden, Japan) using the
oscillometric principle with the subject in supine position.
Furthermore, in the last week of each treatment period blood pressure was measured at
home by 24-h Ambulatory Blood Pressure Monitor (ABPM) using a fully automated device
Danshen and Cardiovascular Risk Factors
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(Mobil-O-Graph NG, I.E.M. GmbH, Germany). ABPM results were expressed as mean total,
day (from 8.00 a.m. to 10.59 p.m.) and night (from 11.00 pm to 7.59 a.m.) blood pressure.
Forearm vasodilator response to acetylcholine and sodium nitroprusside
Forearm blood flow (FBF) was assessed by venous occlusion plethysmography using mercury-
in-silastic strain gauges (Hokanson EC4. Hokanson, Inc) as previously described [26]. The
experiments started at 8.30 a.m. after an overnight fast in a quiet, temperature controlled room
(23°C–24°C). Study medication was ingested at home, prior to visiting our clinical research
department. The subjects were studied after 24 hours of caffeine abstinence. The brachial artery
of the non-dominant arm (experimental forearm) was cannulated (27-gauge needle, Braun,
Melsungen, Germany) for infusion of vasodilators. FBF was measured at both forearms simul-
taneously. The upper arm cuffs were inflated using a rapid cuff inflator (Hokanson E-20, DE
Hokanson, Bellevue, WA). Wrist cuffs were inflated to 220 mmHg to occlude the hand circula-
tion during the infusion of both vasodilators and their baselines [27]. Forearm volume was
measured with the water displacement method and all drugs were dosed per 100 ml forearm
tissue with a constant infusion rate of 100 μl.dl-1.min-1 during infusion of solvent (baseline
recordings) as well as during infusion of increasing doses of vasodilators
After complete instrumentation, a 30 minute equilibration period followed, after which
baseline measurements were performed with infusion of saline. Subsequently, three increasing
doses of acetylcholine (0.5, 2.0 and 8.0 μg.dl-1.min-1, 10 mg/ml dry powder, dissolved to its
final concentration with saline, Novartis, Greece) were infused into the brachial artery. Acetyl-
choline stimulates endothelial muscarinic receptors thereby activating nitric oxide synthase.
This results in endothelial release of nitric oxide (NO) causing vasodilation[26]. Each dose was
infused for 5 minutes and FBF was measured. After the last acetylcholine dose, a 30 minutes
equilibration period followed. Subsequently, baseline measurements were performed with the
infusion of glucose 5% solution. Subsequently, three increasing doses of sodium nitroprusside
(0.06, 0.20 and 0.60 μg.dl-1.min-1, 25 mg/ml, dissolved to its final concentration with glucose
5% solution, Clinical Pharmacy, Radboud university medical centre), a NO-donor and endo-
thelium-independent vasodilator [28] were infused. Again, each dose was infused for 5 minutes
and FBF was measured. FBF registrations of the last 2 minutes of each dosage of vasodilator
were averaged to a single value for data analysis.
Hemostatic and rheological parameters
Screening for primary hemostasis abnormalities was performed using the platelet function ana-
lyzer (PFA-100, Siemens, Germany). The closure time was measured with the collagen epi-
nephrine and collagen-ADP cassette. Normal reference ranges for the collagen epinephrine
cassette is 170 sec with an inter assay variation of 12.4%. Normal reference ranges for the col-
lagen ADP cassette is 120 sec with an inter-assay variation of 12.7%.
VonWillebrand Factor (vWF) antigen levels were measured using the Asserachrom VWF:
Ag ELISA from STAGO. The Lower Limit Of Quantification (LLOQ) of this assay is 12.5%
with an inter-assay variation coefficient of 4.7%. Reference intervals are blood group dependent
and ranges from 50–150% (blood group O) up to 70–210% (blood group AB).
The effect of Danshen on coagulation and fibrinolysis was measured using the Nijmegen
Hemostasis Assay which measures thrombin and plasmin generation in time [29]. The throm-
bin generation curve represents the following parameters: (i) lag-time, the time to the start of
thrombin formation; (ii) thrombin peak time, i.e. the time when thrombin production reaches
maximal velocity; (iii) thrombin peak height, the maximal velocity of thrombin generation;
and (iv) the area under the curve (AUC) for the total amount of thrombin formed. Plasmin
Danshen and Cardiovascular Risk Factors
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generation is described by: (v) fibrin lysis time, the time between the initiation of thrombin
generation and the time plasmin generation reaches maximal velocity; (vi) plasmin peak-
height, the maximal velocity of plasmin production; and (vii) plasmin potential, area under the
curve that represents the total amount of plasmin generated. The inter-assay variation of
thrombin generation parameters varies from 5.9% (AUC) to 25% (lag time thrombin genera-
tion). The inter-assay variation of plasmin generation parameters varies from 10% (plasmin
peak height) to 14% (plasmin potential).
All hemostatic parameters were measured at the Department of Laboratory Medicine of the
Radboud university medical Centre.
Blood viscosity was determined in vitro at a temperature of 37°C and at a shear rate of 3.16
s-1 with the viscometer LS300 (ProRheo GmbH, Germany).
TCM-qualification of “blood stasis”
Two TCM practitioners independently determined the presence of “blood stasis” by pulse and
tongue diagnosis and interrogation at baseline and after both treatment periods. The TCM
practitioners were asked to categorize patients as having definite “blood stasis” (score 1), defi-
nite absence of “blood stasis” (score 3) or some characteristics of “blood stasis” but not fulfilling
the criteria for a full qualification (score 2). Kappa values and polychoric correlations were cal-
culated to estimate the agreement of both TCM-practitioners for the three visits separately.
The polychoric correlation was calculated in addition to kappa-value since the distribution of
the diagnostic score appeared not homogeneous with overpresentation of score 2, a situation
that makes the kappa-value very sensitive to a single disagreement.
Calculations and statistical analysis
We considered a change of 0.225 mmol/l in primary endpoint LDL-cholesterol between treat-
ment groups as clinically relevant. Assuming a test-to-test correlation coefficient of 0.7 we
would require a total of 20 subjects to detect a change of 0.225 mmol/l in LDL-cholesterol with
a power of 80% at a significance level of 0.05 (Zα = 1.96). When the test-to-test correlation was
0.5, a study including 20 participants would be able to detect a difference of 0.3 mmol/l. Drop-
outs were replaced.
Differences in means of laboratory results and blood pressure measurements were tested by
paired Student’s t-test or Wilcoxon signed rank test for non-normally distributed data. In addi-
tion, the effect of Danshen on plasma lipids and ApoB-lipoprotein was analyzed with the CROS
analysis according to Senn [30]. For each treatment period, we calculated the difference between
before- and after measurement. Next, the difference between period one and period two was
calculated. These differences were compared between the two randomisation groups using an
independent sample t-test. To explore potential carry-over effects, we investigated treatment by
period interactions. For this purpose, we compared the placebo-effect between the two rando-
misation groups as well as the Danshen-effect with an independent samples t-test.
Repeated measures analysis of variances (ANOVA) was used to assess the effect of Danshen
on FBF-response to acetylcholine and nitroprusside. Statistical analyses were performed using
Graphpad 5.0. Results are expressed as mean ± Standard Error of the Mean (SEM), unless oth-
erwise indicated. Significance was set at a two-sided p-value of less than 0.05.
Ethics statement
This study was conducted in accordance with the principles outlined in the Declaration of Hel-
sinki and Good Clinical Practice (GCP) guidelines. The local Institutional Review Board (‘Com-
missie Mensgebonden Onderzoek’(CMO) Arnhem/Nijmegen, registration number: CMO 2011/
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326) approved the study and all subjects gave written informed consent before participation. The
final protocol including the final amendments as marked in tracked changes is provided as sup-
plemental information. The trial was registered at clinicaltrials.gov (NCT01563770).
Results
The first participant was included on May 10, 2012. The 20th fully evaluable and last participant
visited our research centre on March 28, 2013. Twenty-three of the 36 initially screened sub-
jects underwent randomization and were enrolled in the study. One participant withdrew
before start of the study medication. One participant discontinued the intervention due to a
facial nerve paralysis during Danshen treatment. Furthermore, one subject was excluded from
statistical analyses because of insufficient compliance to the trial protocol. See Table 1 for base-
line characteristics of the remaining 20 evaluable participants. All 20 evaluable participants
were included in all analyses.
Lipids
Danshen treatment did not affect High Density Lipoprotein (HDL) cholesterol, triglycerides
and Apolipoprotein B. However, total cholesterol and LDL cholesterol were significantly higher
after Danshen treatment compared to placebo, approximately 0.3 mmol/l (Table 2). Baseline
levels of total cholesterol and LDL cholesterol were not different for both treatment periods.
Furthermore, total cholesterol and LDL cholesterol were slightly but significantly higher after
treatment with Danshen compared to baseline values (p< 0.01) while placebo treatment did
not change baseline levels. When the effect on Danshen was expressed as change from baseline
and corrected for the changes observed during placebo treatment, LDL-cholesterol was signifi-
cantly increased (Table 3) while other lipid fractions were not affected. Analysis of potential
carry-over effects did not reveal any significant treatment by period interactions.
Blood pressure
24 h ABPM did not change in response to Danshen treatment (Table 4). The total number of
measurements during ABPM was 67±9 of which 17±2 (mean±standard deviation (SD)) during
the night with Danshen and 63±10 and 17±2 with placebo treatment, respectively.
Table 1. Baseline characteristics.
Characteristics of 20 participating subjects (mean ± SD)
Age (years) 58.0±7.7
Sex (male:female) 14:6
Weight (kg) 86.4±18.9
BMI (kg/m2) 28.6±5.6
Blood pressure systolic (mmHg) 156±9
Blood pressure diastolic (mmHg) 94±5
Total cholesterol (mmol/l) 6.2±0.7
Triglycerides (mmol/l) 1.9±1.3
HDL- cholesterol (mmol/l) 1.3±0.4
LDL- cholesterol (mmol/l) 4.0±0.5
Apolipoprotein B (g/l) 1.1±0.2
Fasting glucose (mmol/l) 5.5±0.6
HbA1c (%) 5.7±0.3
Antihypertensives (%) n = 10 (50) Diuretics n = 6 (30), Beta-blockers n = 4 (20)
doi:10.1371/journal.pone.0128695.t001
Danshen and Cardiovascular Risk Factors
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Twenty minute automatic blood pressure measurements were performed prior to placebo
and Danshen administration (‘baselines’). Again, both systolic and diastolic blood pressures
were not different at baseline (systolic blood pressures before Danshen 140±3 mmHg and
before placebo 140±3 mmHg. Corresponding values for diastolic blood pressure were 85±2
mmHg and 85±2 mmHg, respectively).
Forearm vascular responses to acetylcholine
Infusion of acetylcholine induced a dose-dependent increase in FBF in the experimental fore-
arm while FBF did not change in the non-experimental forearm. Danshen treatment did not
alter the FBF in response to acetylcholine compared to placebo. With Danshen, FBF increased
from 2.3±0.2 ml.dl-1.min-1 during saline to 7.5±0.8, 12.1±1.0 and 16.3±1.3 ml.dl-1.min-1 during
acetylcholine 0.5, 2.0 and 8.0 μg.dl-1.min-1 respectively compared to 2.6±0.4 during saline and
8.2±0.9, 12.6± 1.1 and 16.6± 1.3 ml.dl-1.min-1 during acetylcholine with placebo (Fig 3). Com-
parable results were obtained when data were expressed as absolute and relative changes in
FBF from baseline.
Table 2. Lipid levels before and after treatment with danshen and placebo. Results are provided as mean±SEM. Baseline values did not significantly dif-
fer between Danshen and placebo treatment.
Danshen Placebo
Baseline Treatment Baseline Treatment
Total cholesterol (mmol/l) 5.61±0.15 5.84±0.18* # 5.60±0.19 5.55±0.18
Triglycerides (mmol/l) 1.76±0.27 1.75±0.22 1.71±0.25 1.81±0.24
HDL cholesterol (mmol/l) 1.23±0.07 1.23±0.07 1.21±0.06 1.22±0.07
LDL cholesterol (mmol/l) 3.67±0.12 3.82±0.14* # 3.63±0.16 3.52±0.16
Apolipoprotein B (g/l) 1.00±0.04 1.02±0.04¶ 0.99±0.05 0.97±0.04
* p< 0.01 compared to baseline.
¶ p <0.05 and
# p< 0.01 compared to treatment with placebo
doi:10.1371/journal.pone.0128695.t002
Table 3. The absolute changes in lipid levels during treatment with Danshen, corrected for the changes during treatment with placebo. CROS anal-
ysis according to Senn (see statistical section for explanation). A negative number indicates a decrease by Danshen.
Treatment effect 95% conﬁdence interval p-value
Total cholesterol (mmol/l) 0.27 -0.05–0.59 0.089
Triglycerides (mmol/l) -0.13 -0.50–0.25 0.478
HDL-cholesterol (mmol/l) -0.02 -0.09–0.06 0.692
LDL-cholesterol (mmol/l) 0.29 0.02–0.55 0.037
ApoB lipoprotein (mmol/l) 0.03 -0.02–0.08 0.167
doi:10.1371/journal.pone.0128695.t003
Table 4. Measurement of Systolic/Diastolic blood pressure before and after treatment with Danshen
or placebo. Results are provided as mean±SEM. BP: blood pressure. ABPM: 24-h Ambulatory Blood Pres-
sure Monitoring.
ABPM Danshen Placebo
total BP (mmHg) 139±4/89±3 136±4/87±2
day BP (mmHg) 142±4/91±3 139±4/90±2
night BP (mmHg) 130±4/82±2 130±4/79±2
doi:10.1371/journal.pone.0128695.t004
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Forearm vascular responses to sodium nitroprusside
Infusion of sodium nitroprusside induced a dose-dependent increase in FBF in the experimental
forearm. FBF did not change in the non-experimental forearm. Treatment with Danshen did
not affect vascular responses to sodium nitroprusside. FBF was 2.6±0.3 ml.dl-1.min-1 during glu-
cose and 5.0± 0.4, 7.8± 0.6 and 11.5± 0.8 ml.dl-1.min-1 during sodium nitroprusside 0.06, 0.20
and 0.60 μg.dl-1.min-1, respectively after Danshen treatment, compared to 3.0±0.5 at baseline
and 5.3± 0.5, 7.7± 0.7 and 11.3± 1.0 ml.dl-1.min-1 during nitroprusside after placebo (Fig 3).
Metabolic and inflammatory parameters
Treatment with Danshen did not affect fasting plasma glucose levels (Danshen 5.7±0.1 mmol/l
vs placebo 5.8±0.2 mmol/l, p = 0.48) and HbA1c levels (5.8±0.09% and 5.7±0.08%, respectively,
p = 0.45). Also fasting insulin levels, HOMA-IR and HOMA-B did not change during Danshen
treatment.
C-reactive protein (CRP) levels were not significantly different after Danshen (2.9±0.7 mg/
l) compared to placebo treatment (2.7±0.7 mg/l).
The markers of oxidative stress TBARs and FRAP did not change during Danshen treat-
ment compared to placebo (TBARs 0.09±0.01 vs 0.09±0.01 μmol/mg protein and FRAP 268
±11 vs 267±11 μM/mg protein). Furthermore, there were no differences in oxidized LDL,
Intercellular Adhesion Molecule (ICAM), Vascular Cell Adhesion Molecule (VCAM) and E-
selectin between Danshen and placebo treatment (data not shown). Danshen did not change
body weight (data not shown).
Hemostatic and rheological parameters
Danshen treatment did not change von Willebrand factor antigen levels compared to placebo
(112±9% vs 113±9%). The PFA with collagen and epinephrine was 132±7 s when treated with
Danshen and 148±7 s when treated with placebo, both within the normal range (p = 0.048 for
comparison between Danshen and placebo). Furthermore, the PFA with collagen and ADP
was not different between the two treatment periods (97±4 s and 100±4 s, respectively). Taking
both PFA tests together, we interpret these data as that Danshen does not relevantly affect
platelet function.
The coagulation parameters measured by thrombin generation as well as fibrinolysis param-
eters measured by plasmin generation were not altered by Danshen treatment (Fig 4).
Blood viscosity at a shear rate of 3.16 sˉ¹ was not different after treatment with Danshen
(14.4±0.9 mPass) compared to placebo (14.2±0.8 mPass). However, hematocrit levels were
Fig 3. Assessment of endothelial function. Forearm blood flow in response to acetylcholine in the experimental arm (solid lines) and in the non
experimental arm (dashed lines) in response to acetylcholine (left panel; dosage 0.5, 2.0, 8.0 μg.dl-1.min-1) and sodium nitroprusside (right panel; dosage
0.06, 0.20 and 0.60 μg.dl-1.min-1), during Danshen (dark grey circles) or placebo (light grey squares).
doi:10.1371/journal.pone.0128695.g003
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significantly higher after treatment with Danshen (44 l/l vs 43 l/l, p = 0.048). When expressing
blood viscosity per l/l of hematocrit we did not find an effect of Danshen on viscosity either.
TCM-qualification ‘Blood Stasis’
Only two out of the twenty participants (10%) were qualified as having ‘blood stasis’ at inclu-
sion. In both subjects blood stasis was not observed in the following visits. The kappa values, as
a measure of between-observer agreement for the diagnosis of blood stasis were 0.19 for TCM
visit at baseline, 0.67 for TCM visit after the first treatment period, and -0.08 for TCM visit
after the second treatment period. In addition a polychoric correlation was calculated which
was 0.43, 0.99 and 0.12 for the first, second and third visit, respectively.
Side effects and safety
Most reported side effects during Danshen treatment were headache (n = 5), dizziness (n = 3),
change in stool frequency (n = 3) and flatulence (n = 2). One serious adverse event occurred
during Danshen treatment: a peripheral facial nerve paralysis.
Discussion
This study did not find beneficial effects of four weeks of treatment with Danshen on cardio-
vascular risk factors. This is based on the observation that Danshen does not reduce LDL and
triglyceride levels and does not decrease blood pressure. Furthermore, Danshen had no effect
on endothelial function, markers of inflammation, oxidative stress and glucose metabolism nor
on hemostatic and rheological markers.
These results are in contrast with previous studies. A number of explanations may underlie
the lack of reduction of cardiovascular risk markers in this study. First, we only used Danshen
and not a combination of Chinese herbs.
Tan et al. have shown that a combination of 3 Chinese herbs, including Danshen, decreased
fasting triglycerides, cholesterol and non-esterified fatty acids in rats with metabolic syndrome
[14]. The Fufang Danshen dripping pill, which is a composite of Salvia miltiorrhiza, Panax
notogingseng and Cinnamomum camphora, reduced triglycerides, total cholesterol and LDL
cholesterol levels [9].
Second, there are over 80 components of Danshen of which 3 lipophilic and 3 hydrophilic
components seem to be the major active components [9, 31]. Our Danshen product was pro-
duced via water-extraction method. Possibly, a low concentration in the water-extract of
pharmacologically active lipophilic compounds, including tanshinones, led to a lack of efficacy
Fig 4. Results of the Nijmegen Hemostasis Assay. A. Thrombin generation. B. Plasmin generation measured by fibrinolysis time.
doi:10.1371/journal.pone.0128695.g004
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of Danshen. Unfortunately, an alcohol-extract of Danshen is not available in the Netherlands
for human use.
Third, the selection of participants was based on evidence-based criteria of increased cardio-
vascular risk, i.e. increased LDL cholesterol or triglyceride levels and hypertension. The TCM
qualification “blood stasis” was only made in 2 out of the 20 participants. Since according to
the TCM theory Danshen is used to treat “blood stasis”, advocators of this theory could argue
that the selected population might not be suitable to detect any cardiovascular benefit. It is not
known what diagnosis according to evidence-based medicine corresponds with this TCM-
qualification. Therefore, we cannot exclude the possibility that Danshen is effective in reducing
plasma LDL-cholesterol in a subgroup of patients who have “blood stasis” as opposed to the
observed increase in plasma LDL-cholesterol in those who are at increased cardiovascular risk
according to evidence-based criteria. However, our observed low reproducibility of the obser-
vation ‘blood stasis’ and overpresentation of intermediate test results support our decision not
to include this TCM-qualification in the inclusion criteria of this trial.
In our study Danshen (water extract) actually increased LDL and total cholesterol levels
compared to placebo. This increment in cholesterol levels has also been observed for another
food product, namely coffee. It has been shown that boiled, but not filtered, coffee increases
total cholesterol and LDL cholesterol [32]. The hypercholesterolemic factor in boiled coffee is
retained by the filter paper and eventually this factor was identified as cafestol [33, 34]. Possi-
bly, the method of preparation of Danshen produced or preserved a “hypercholesterolemic fac-
tor” that was not produced by methods used by others.
Danshen did not reduce endothelium-dependent vasodilation which suggests that the
observed increase in LDL cholesterol of approximately 0.3 mmol/l is too small to have a signifi-
cant impact on cardiovascular risk. Indeed, endothelium-mediated vasodilation predicts cardio-
vascular disease and is responsive to changes in plasma cholesterol [35–38]. The Cholesterol
Treatment Trialists’ (CTT) Collaboration has shown that each 1 mmol/l reduction in LDL cho-
lesterol reduces the absolute risk of major cardiovascular events with 20% [39]. If we intrapolate
these epidemiological observations and assume generalizability of our findings, our observed
increase of 0.3 mmol/l in LDL cholesterol would translate into a small increment of 7% in abso-
lute risk of cardiovascular disease. Based on the demographic data of our study population and
current cardiovascular risk tables available for this Dutch population, absolute 10-year cardio-
vascular risk of our subjects to develop a cardiovascular event is 19% for male non-smokers and
35% for male smokers. The water extract of Danshen could theoretically increase these risks to
20.3% and 37.5% for male non-smokers and smokers respectively. However, this projected
increase in cardiovascular risk may overestimate the real impact of Danshen on cardiovascular
risk, since the increase in LDL-cholesterol was not accompanied by a detectable increase in oxi-
dized LDL cholesterol. Therefore, the impact of Danshen on lipid profile was probably too
small to be reflected by a detectable change in acetylcholine-induced forearm vasodilation.
The strength of our study is the randomized, double-blind, placebo controlled design with
objective and reproducible endpoints. The cross-over design is potentially limited by carry-
over effects. However, we did not detect an order-effect and baseline measurements in blood
pressure and plasma lipids did not differ prior to the two treatment periods.
Conclusion
Four weeks of treatment with the herbal product Danshen (water extract) slightly increased
LDL-cholesterol without affecting a wide variety of other risk markers or endothelium-depen-
dent vasodilation, an early marker of vascular injury. These results do not support the use of
Danshen water-extract as a single agent to treat risk factors of atherosclerosis.
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